Drug Trial Radar · NCT02870205
Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)
Last checked: Nov 19, 2026Latest source record: Apr 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,176
Actual
Start
Aug 2016
Primary completion
Jan 2017
Study completion Jan 2017
Sponsor
- Lead sponsor
- Glenmark Specialty S.A.Industry
- Sponsor type
- Industry
- First posted
- Aug 17, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study to evaluate the efficacy, safety and tolerability of GSP 301 NS compared with placebo NS and individual monotherapy formulations for the treatment of Seasonal Allergic Rhinitis (subjects 12 years of age and older)
Conditions
- Seasonal Allergic Rhinitis (SAR)
Interventions
GSP 301 NSDrug
2 spray in each nostril twice daily for 14 days
GOM-NSDrug
2 spray in each nostril twice daily for 14 days
GMM-2 NSDrug
2 spray in each nostril twice daily for 14 days
GSP 301 placebo NSDrug
2 spray in each nostril twice daily for 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Average AM and PM Subject-reported 12-hour Reflective Total Nasal Symptom Score (rTNSS)Time frame: Baseline and day 14
Locations
43 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site 406
Mission Viejo, California
Investigational Site 414
Orange, California
Investigational Site 435
San Diego, California
Investigational Site 420
Centennial, Colorado
Investigational Site 444
Colorado Springs, Colorado
Investigational Site 428
Aventura, Florida
Investigational Site 412
Miami, Florida
Investigational Site 436
Bethesda, Maryland
Investigational Site 432
South Dartmouth, Massachusetts
Investigational Site 426
Minneapolis, Minnesota
Investigational Site 403
Plymouth, Minnesota
Investigational Site 443
Columbia, Missouri
Investigational Site 441
Rolla, Missouri
Investigational Site 440
St Louis, Missouri
Investigational Site 405
Bellevue, Nebraska
Investigational Site 434
Skillman, New Jersey
Investigational Site 408
Rochester, New York
Investigational Site 418
Rockville Centre, New York
Investigational Site 402
High Point, North Carolina
Investigational Site 427
Raleigh, North Carolina
Investigational Site 419
Cincinnati, Ohio
United States 404
Cincinnati, Ohio
United States 407
Edmond, Oklahoma
Investigational Site 410
Oklahoma City, Oklahoma
Investigational Site 424
Tulsa, Oklahoma
Investigational Site 411
Pittsburgh, Pennsylvania
Investigational Site 416
Spartanburg, South Carolina
Investigational Site 415
Austin, Texas
Investigational Site 442
Austin, Texas
Investigational Site 417
Boerne, Texas
Investigational Site 421
Dallas, Texas
Investigational Site 430
Dallas, Texas
Investigational Site 431
El Paso, Texas
Investigational Site 433
Kerrville, Texas
Investigational Site 422
New Braunfels, Texas
Investigational Site 401
San Antonio, Texas
Investigational Site 413
San Antonio, Texas
Investigational Site 425
San Antonio, Texas
Investigational Site 437
San Antonio, Texas
Investigational Site 400
Waco, Texas
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.